NDAORALFILM
Approved
Apr 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
RIZAFILM (rizatriptan benzoate) by Jubilant Therapeutics is 5-ht 1b/1d receptors. Approved for migraine attacks, cluster headache (), migraine. First approved in 2023.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIZAFILM is a novel oral film formulation of rizatriptan benzoate, a selective 5-HT1B/1D receptor agonist approved in April 2023 for acute migraine and cluster headache treatment. It works by binding to serotonin receptors on intracranial blood vessels and trigeminal nerve sensory fibers, causing cranial vasoconstriction and inhibiting pro-inflammatory neuropeptide release.
Peak7.7 years to LOE
RIZAFILM is in peak commercial lifecycle with 7.9 years of patent protection remaining, suggesting sustained team investment and growth opportunity for brand-focused roles.
Mechanism of Action
5-HT 1B/1D receptors. MAXALT presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT 1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
Indications (3)
Worked on RIZAFILM at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.